stockrowQuest Diagnostics Incorporated
DGX Healthcare Diagnostics & Research
Quest Diagnostics Incorporated’s revenue for fiscal 2025 (year ended December 2025) was $11.0 billion, up 11.8% from fiscal 2024.
- Revenue
- +9.98%
- EPS
- +29.4%
- Free cash flow
- +6.21%
- Total debt
- −2.20%
Quarter to September 2026, against a year earlier
Follow DGX
Alert me
Quest Diagnostics Incorporated (DGX) Net income
Quest Diagnostics Incorporated's net income for fiscal 2025 was $1.0B, up 13.6% from $921.0M in fiscal 2024. Over the twelve months to 30 September 2026 it was $1.2B. Over the past ten years it has ranged from $696.0M (fiscal 2016) to $2.1B (fiscal 2021); the current reading is higher than 82% of that period. Quest Diagnostics Incorporated ranks 6th of 49 Diagnostics & Research companies by net income.
Net income, annual
Embed this chart
Annual newest first
| Period | Net income | Change |
|---|---|---|
| FY2025 | $1.0B | 13.57% |
| FY2024 | $921.0M | 1.43% |
| FY2023 | $908.0M | (10.54%) |
| FY2022 | $1.0B | (51.20%) |
| FY2021 | $2.1B | 38.76% |
| FY2020 | $1.5B | 65.45% |
| FY2019 | $906.0M | 14.97% |
| FY2018 | $788.0M | (4.37%) |
| FY2017 | $824.0M | 18.39% |
| FY2016 | $696.0M | (7.57%) |
Quarterly newest first
| Period | Net income | Change |
|---|---|---|
| Sep 2026 | $326.0M | (2.40%) |
| Jun 2026 | $334.0M | 26.52% |
| Mar 2026 | $264.0M | 3.13% |
| Dec 2025 | $256.0M | (1.16%) |
| 43 more quarters | Free account |
Against its own ten years
Net income against peers
| Company | Net income |
|---|---|
| IQV IQVIA Holdings Inc. compare | $1.4B |
| DGX Quest Diagnostics Incorporated | $1.2B |
| LH Labcorp Holdings Inc. compare | $1.0B |
| MTD Mettler-Toledo International, Inc. compare | $934.1M |
| ILMN Illumina, Inc. compare | $895.0M |
| MEDP Medpace Holdings, Inc. compare | $517.8M |
| RVTY Revvity Inc. compare | $253.2M |
| WAT Waters Corporation compare | $98.2M |
| GH Guardant Health, Inc. compare | −$485.1M |
What Net income is
Net Income tells an investor how much profit a company kept in a period after every cost, interest charge and tax.
Reported line item
More on DGX
- Revenue
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement